China Resources Boya Bio-pharmaceutical GroupLtd Past Earnings Performance
Past criteria checks 0/6
China Resources Boya Bio-pharmaceutical GroupLtd's earnings have been declining at an average annual rate of -5.8%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been declining at an average rate of 3.9% per year. China Resources Boya Bio-pharmaceutical GroupLtd's return on equity is 2.5%, and it has net margins of 10.9%.
Key information
-5.8%
Earnings growth rate
-10.4%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | -3.9% |
| Return on equity | 2.5% |
| Net Margin | 10.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Investors Can Find Comfort In China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Earnings Quality
Nov 01
A Look At The Intrinsic Value Of China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)
Oct 01Market Participants Recognise China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) Earnings
Sep 12Does China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Have A Healthy Balance Sheet?
Jul 25China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) P/E Is On The Mark
Jun 12China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Is Increasing Its Dividend To CN¥0.30
Apr 26Is China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Using Too Much Debt?
Apr 22China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Conservative Accounting Might Explain Soft Earnings
Apr 01What Does The Future Hold For China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)? These Analysts Have Been Cutting Their Estimates
Mar 31Revenue & Expenses Breakdown
How China Resources Boya Bio-pharmaceutical GroupLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,707 | 186 | 567 | 67 |
| 30 Jun 24 | 2,007 | 228 | 632 | 60 |
| 31 Mar 24 | 2,295 | 219 | 714 | 77 |
| 31 Dec 23 | 2,652 | 237 | 777 | 68 |
| 30 Sep 23 | 2,866 | 478 | 858 | 62 |
| 30 Jun 23 | 2,901 | 479 | 906 | 65 |
| 31 Mar 23 | 2,910 | 499 | 913 | 53 |
| 31 Dec 22 | 2,759 | 432 | 926 | 50 |
| 30 Sep 22 | 2,722 | 439 | 955 | 43 |
| 30 Jun 22 | 2,754 | 426 | 971 | 38 |
| 31 Mar 22 | 2,681 | 347 | 962 | 58 |
| 31 Dec 21 | 2,651 | 345 | 970 | 59 |
| 30 Sep 21 | 2,667 | 360 | 992 | 93 |
| 30 Jun 21 | 2,586 | 297 | 1,018 | 97 |
| 31 Mar 21 | 2,528 | 265 | 1,033 | 79 |
| 31 Dec 20 | 2,513 | 260 | 1,030 | 89 |
| 30 Sep 20 | 2,664 | 332 | 1,058 | 95 |
| 30 Jun 20 | 2,755 | 374 | 1,060 | 99 |
| 31 Mar 20 | 2,867 | 433 | 1,104 | 99 |
| 31 Dec 19 | 2,909 | 426 | 1,146 | 93 |
| 30 Sep 19 | 2,867 | 501 | 1,105 | 64 |
| 30 Jun 19 | 2,735 | 491 | 1,042 | 57 |
| 31 Mar 19 | 2,609 | 486 | 987 | 49 |
| 31 Dec 18 | 2,388 | 469 | 902 | 45 |
| 30 Sep 18 | 2,307 | 419 | 853 | 38 |
| 30 Jun 18 | 2,012 | 390 | 719 | 52 |
| 31 Mar 18 | 1,732 | 362 | 631 | 42 |
| 31 Dec 17 | 1,390 | 357 | 513 | 35 |
| 30 Sep 17 | 1,132 | 316 | 367 | 23 |
| 30 Jun 17 | 1,085 | 324 | 347 | 0 |
| 31 Mar 17 | 994 | 301 | 279 | 0 |
| 31 Dec 16 | 947 | 272 | 270 | 0 |
| 30 Sep 16 | 839 | 227 | 242 | 0 |
| 30 Jun 16 | 720 | 187 | 217 | 0 |
| 31 Mar 16 | 615 | 145 | 196 | 0 |
| 31 Dec 15 | 543 | 152 | 178 | 0 |
| 30 Sep 15 | 498 | 138 | 164 | 0 |
| 30 Jun 15 | 472 | 130 | 158 | 0 |
| 31 Mar 15 | 452 | 130 | 149 | 0 |
| 31 Dec 14 | 438 | 104 | 141 | 0 |
| 30 Sep 14 | 366 | 96 | 107 | 0 |
| 30 Jun 14 | 321 | 89 | 91 | 0 |
| 31 Mar 14 | 278 | 85 | 73 | 0 |
| 31 Dec 13 | 245 | 82 | 59 | 0 |
Quality Earnings: 300294 has a large one-off loss of CN¥325.5M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 300294's current net profit margins (10.9%) are lower than last year (16.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300294's earnings have declined by 5.8% per year over the past 5 years.
Accelerating Growth: 300294's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300294 had negative earnings growth (-61.1%) over the past year, making it difficult to compare to the Biotechs industry average (0.08%).
Return on Equity
High ROE: 300294's Return on Equity (2.5%) is considered low.